Back to Search
Start Over
Current Opinion on the use of Direct Oral Anticoagulants for the Prophylaxis of Venous Thromboembolism among Medical Inpatients
- Source :
- Therapeutics and Clinical Risk Management
- Publication Year :
- 2021
- Publisher :
- Informa UK Limited, 2021.
-
Abstract
- Venous thromboembolism (VTE) is a known cause of morbidity and mortality, especially among acutely ill medical patients. Although VTE prophylaxis is part of post-discharge clinical care in surgical patients, there is controversy regarding its use in acutely ill medical patients and the current guideline statements suggest against its routine use. Recent clinical trials (APEX, MAGELLAN and MARINER) compared the safety and efficacy of direct oral anticoagulants (including betrixaban and rivaroxaban) with the standard of the care, enoxaparin, to identify the risk–benefit tradeoff. In this review, we summarized the key findings from these trials and substudies and recent updates in society guidelines regarding VTE prevention. In addition, we discussed the potential barriers, cost-effectiveness, and COVID-19 with respect to the implementation of extended-duration or post-discharge usage of direct oral anticoagulants.
- Subjects :
- medicine.medical_specialty
Coronavirus disease 2019 (COVID-19)
Review
030204 cardiovascular system & hematology
Vte prophylaxis
03 medical and health sciences
chemistry.chemical_compound
0302 clinical medicine
Medicine
Pharmacology (medical)
030212 general & internal medicine
betrixaban
General Pharmacology, Toxicology and Pharmaceutics
Intensive care medicine
rivaroxaban
thromboembolic events
Rivaroxaban
Chemical Health and Safety
business.industry
enoxaparin
General Medicine
Guideline
Clinical trial
chemistry
major bleeding
Betrixaban
medically ill
business
Safety Research
Venous thromboembolism
Surgical patients
medicine.drug
Subjects
Details
- ISSN :
- 1178203X
- Volume :
- 17
- Database :
- OpenAIRE
- Journal :
- Therapeutics and Clinical Risk Management
- Accession number :
- edsair.doi.dedup.....48bb7aba73e15c1ccff45d770eca90ab